Xgeva 120mg (Denosumab) Injection

Xgeva 120 mg Injection (denosumab) has several important warnings and precautions that patients and healthcare providers should be aware of:

Hypocalcemia: Xgeva can cause severe symptomatic hypocalcemia. It is crucial to correct any pre-existing low calcium levels before starting treatment. Patients should be monitored for calcium levels, especially during the initial weeks of therapy, and should receive adequate calcium and vitamin D supplementation.

Osteonecrosis of the Jaw (ONJ): There is a risk of osteonecrosis of the jaw in patients receiving Xgeva. An oral examination should be conducted before starting treatment, and invasive dental procedures should be avoided during therapy. Patients should be monitored for symptoms such as jaw pain or swelling.

Atypical Femoral Fractures: Patients should be evaluated for femoral fractures if they experience thigh or groin pain, as atypical femoral fractures have been reported in those taking Xgeva.

Dental Procedures: Patients with unhealed wounds from dental or oral surgery should not receive Xgeva until these wounds are healed to minimize the risk of complications.

Pregnancy and Fetal Risk: Xgeva may cause fetal harm if administered during pregnancy. Women of childbearing potential should be advised about potential risks and should inform their healthcare provider if they become pregnant while on treatment.

Allergic Reactions: Patients should be monitored for signs of severe allergic reactions, including rash, itching, or difficulty breathing, and should seek immediate medical attention if these occur.

Drug Interactions: Inform healthcare providers about all medications being taken, as certain drugs may interact with Xgeva.